孚博生物的重组抗体表达平台,可以根据您提供的抗体序列,基于哺乳动物细胞表达系统,利用高表达载体,转染NS0/CHO/HEK293等已定向驯化细胞,进行重组抗体生产。项目完成后交付1~5mg,> 90% 纯度的重组抗体,也能按要求进行内毒素水平控制(≤1EU/mg)。同时,也可以根据客户的批量生产要求,提供克级的重组抗体。

服务流程:
1. 生物信息学方法分析抗体序列并预测抗体结构
2. 基因合成&亚克隆,1~2周
—抗体结构分析及密码子优化
—基因合成&高表达载体构建
3. 质粒抽提,1-2周
—转染级别质粒抽提
4. 瞬时转染表达与纯化,2-3周
—瞬时转染
—表达小试与检测
—亲和纯化与多步纯化
—质检QC/QA
5. 稳定细胞株筛选(可选)
—大量及重复重组抗体生产
孚博生物完善成熟的哺乳动物蛋白表达平台,结合抗体测序、抗体纯化、抗体亲和力成熟等生产平台能为客户提供重组抗体定制服务,包含鼠源单克隆抗体测序及表达、更换恒定区亚型的嵌合抗体表达,抗体人源化改造及表达等服务。
孚博生物定制优势:
1. 定制生产周期短,小量表达周期4周起;
2. 克级重组抗体生产,保障您后续项目需求;
3. 重组蛋白形式多样,也可以根据您的需要定制生产治疗性药物抗体生物类似物;
4. 定制方案灵活,可根据您的项目要求,为您提供内毒素控制、SEC-HPLC纯化、小量或者克级重组抗体生产等服务。
我们已有数十种重组抗体成功表达生产的经验,包括全长抗体、scFv、Fab片段、单域抗体(sdAb)、纳米抗体、嵌合抗体及多样化的Fc融合蛋白等多种形式的重组抗体,也可以根据您的需要定制生产药物抗体生物类似物等。
热门靶点重组抗体现货产品,多种包装、纯度和标记助力科研:
EGFR,VEGF,PD-1,GITR,TIM-3,LAG-3,BTLA,CD27,CD73,TGFbeta,DLL4,VEGFR2,ANGPT2,IL-6,HGF,cMET,HER3,LGR5,ICOS,CTLA-4,CD47,HER2,4-IBB,HIV-1 Env,CD4,CD32B,CD79B,CD20,CD95,TfR,BACE1,Tau,EGFRvIII,PD-L1,CD133,EpCAM,CLEC12,TROP2,CEA,FLT3,CD19,CD22,Claudin-18.2,GPC3,5T4,PSMA,CD28,FAP,MSLN,CD40,TA-MUC1,B7-H3,IL-13Ra2,GPA33,MUC16,Epha2,Cadherin-17,TRAIL R2,BCMA,NKp30,CD16,CD30,CD33,CD123,ROR1,CD38,IGF-I R,PSCA,DLL3,OX40,CD3
科研级重组药物抗体,可提供现货和定制服务:
| adalimumab | glembatumumab vedotin | mirzotamab clezutoclax | concizumab | ustekinumab | robatumumab | panobacumab | CAT-2200 |
| alemtuzumab | gosuranemab | mitazalimab | crenezumab | vedolizumab | romilkimab | praluzatamab ravtansine | CBTAU-24.1 |
| alirocumab | GSK 679586 | narnatumab | dapirolizumab pegol | afasevikumab | rontalizumab | radretumab | CDP571 |
| atezolizumab | GSK 933776 | navicixizumab | dostarlimab | AGS-009 | rosopatamab tetraxetan | samalizumab | cevostamab |
| avelumab | ianalumab | NI-0701 | envafolimab | AGS67E | ruplizumab | tarextumab | Chugai SK2 |
| basiliximab | icrucumab | ongericimab | epratuzumab | alsevalimab | sabatolimab | TOL101 | CNTO 2125 |
| belantamab mafodotin | ieramilimab | onvatilimab | etrolizumab | ALX-0141 | sacituzumab govitecan | ulocuplumab | CNTO 4088 |
| belimumab | imalumab | opucolimab | evinacumab | AMG 811 | sasanlimab | vandortuzumab vedotin | CNTO 607 |
| benralizumab | imgatuzumab | PAT-SM6 | faricimab | amivantamab | semorinemab | varlilumab | CNTO5429 |
| bevacizumab | inclacumab | pavurutamab | farletuzumab | apamistamab | seribantumab | vunakizumab | cofetuzumab |
| blinatumomab | indusatumab vedotin | perakizumab | fasinumab | aprutumab | setrusumab | AB023 | demupitamab |
| brentuximab vedotin | iscalimab | petosemtamab | feladilimab | ASG-5ME | sevirumab | AbGn-168 | DISC0280 |
| brodalumab | istiratumab | PF-03732010 | felzartamab | atinumab | sifalimumab | abrilumab | disitamab vedotin |
| brolucizumab | itepekimab | PF-06263507 | figitumumab | azintuxizumab vedotin | simtuzumab | ABX-IL8 | DLX212 |
| burosumab | itolizumab | PF-06342674 | fulranumab | bapotulimab | sonelokimab | actoxumab | DLX212 |
| canakinumab | ivuxolimab | PG110 | galiximab | bepranemab | sonepcizumab | adecatumumab | DX-2647 |
| caplacizumab | labetuzumab govitecan | plamotamab | ganitumab | bivatuzumab mertansine | talacotuzumab | AGS-1C4D4 | elsilimomab |
| cemiplimab-rwlc | lacnotuzumab | prasinezumab | gantenerumab | brontictuzumab | talizumab | alacizumab pegol | erlizumab |
| certolizumab pegol | lacutamab | ralpancizumab | gevokizumab | budigalimab | telazorlimab | amatuximab | ESBA 105 |
| cetuximab | ladiratuzumab vedotin | RO5458640 | girentuximab | CDP484 | tesidolumab | AMG 714 | FM101 |
| daclizumab | landogrozumab | rolinsatamab talirine | lampalizumab | cendakimab | tesnatilimab | anetumab ravtansine | futuximab |
| daratumumab | lecanemab | rosmantuzumab | lebrikizumab | cergutuzumab amunaleukin | tigatuzumab | anrukinzumab | giloralimab |
| denosumab | lendalizumab | SAIT301 | lenzilumab | cibisatamab | tisotumab vedotin | apitegromab | glofitamab |
| dinutuximab | lifastuzumab vedotin | samrotamab vedotin | levilimab | citatuzumab bogatox | TNX-832 | APX005 | H2L6 |
| dupilumab | lirilumab | selicrelumab | ligelizumab | cosibelimab | tomaralimab | ascrinvacumab | Hersintuzumab |
| durvalumab | loncastuximab tesirine | serclutamab talirine | margetuximab | crotedumab | tomuzotuximab | astegolimab | hMAK195 |
| eculizumab | lorvotuzumab mertansine | sibrotuzumab | mirikizumab | CSL311 | tovetumab | avdoralimab | IMC-2C5 |
| efalizumab | lulizumab pegol | siplizumab | mirvetuximab soravtansine | cudarolimab | tregalizumab | balstilimab | Imclone 6.64 |
| elotuzumab | lumiliximab | sirtratumab vedotin | motavizumab | depatuxizumab | trevogrumab | batoclimab | Immunomedics hA19 |
| emapalumab | lutikizumab | sofituzumab vedotin | narsoplimab | dezamizumab | TRU-015 | befovacimab | Immunomedics hA19 |
| emicizumab | LY2525623 | solitomab | nemolizumab | DFRF4539A | tusamitamab ravtansine | bersanlimab | indusatumab |
| enfortumab vedotin-ejfv | marstacimab | tabituximab barzuxetan | netakimab | dilpacimab | urelumab | bezlotoxumab | isecarosmab |
| eptinezumab-jjmr | matuzumab | TAK-701 | nimotuzumab | Duke D2C7 | vanucizumab | BHQ880 | JMW-3B3 |
| erenumab | mavrilimumab | talquetamab | onartuzumab | dusigitumab | vatelizumab | bintrafusp alfa | lilotomab |
| evolocumab | miptenalimab | tamrintamab pamozirine | otelixizumab | duvortuxizumab | veltuzumab | bleselumab | lintuzumab satetraxetan (actinium (225Ac) ) |
| fremanezumab-vfrm | MM-111 | tavolimab | otilimab | elezanumab | vibostolimab | blosozumab | LK-1 |
| galcanezumab-gnlm | murlentamab | teclistamab | patritumab | enavatuzumab | vilobelimab | cabiralizumab | M1295 |
| golimumab | namilumab | telisotuzumab | ravulizumab | encelimab | vobarilizumab | camidanlumab tesirine | manelimab |
| guselkumab | naratuximab emtansine | tepoditamab | retifanlimab | enoblituzumab | vofatamab | cantuzumab mertansine | mavezelimab |
| ibalizumab-uiyk | naxitamab | tibulizumab | rilotumumab | enoticumab | volagidemab | carlumab | MB 311 |
| ibritumomab tiuxetan | nesvacumab | tidutamab | ripertamab | etigilimab | volociximab | cinpanemab | MB 311 |
| inebilizumab-cdon | NG-101 | tilavonemab | rovalpituzumab tesirine | fianlimab | vonlerizumab | cixutumumab | MEDI2045 |
| infliximab | NI-0801 | tilvestamab | rozanolixizumab | flanvotumab | vopratelimab | cobolimab | modotuximab |
| inotuzumab ozogamicin | nipocalimab | timigutuzumab | satralizumab | FR104 | xentuzumab | codrituzumab | MOR-8457 |
| ipilimumab | NIS793 | tinurilimab | serplulimab | gatipotuzumab | zagotenemab | coltuximab ravtansine | NCI m971 |
| isatuximab-irfc | odronextamab | utomilumab | sirukumab | gatralimab | zalifrelimab | crizanlizumab | NCI m972 |
| ixekizumab | oleclumab | vantictumab | solanezumab | GSK1995057 | zanidatamab | cusatuzumab | nimacimab |
| lanadelumab | olinvacimab | vesencumab | spartalizumab | HuMax-IL8 | zelminemab | dacetuzumab | NKTT320 |
| mepolizumab | olokizumab | VGX100 | sutimlimab | icatolimab | zenocutuzumab | dalotuzumab | nurulimab |
| mogamulizumab-kpkc | omburtamab | vibecotamab | tabalumab | idactamab | ziltivekimab | dectrekumab | orilanolimab |
| moxetumomab pasudotox | ontamalimab | vorsetuzumab | tanezumab | ifabotuzumab | zuberitamab | demcizumab | ORY012 |
| natalizumab | ontuxizumab | vulinacimab | teplizumab | iladatuzumab vedotin | abagovomab | denintuzumab mafodotin | OST 577 |
| necitumumab | opicinumab | zanidatamab zovodotin | tezepelumab | IMA-026 | abituzumab | derlotuximab biotin - iodine (131I) | pasotuxizumab |
| nivolumab | oportuzumab monatox | ASK8007 | tiragolumab | imaprelimab | bimagrumab | domagrozumab | PDL241 |
| obinutuzumab | orticumab | avizakimab | tislelizumab | IMC-EB10 | gancotamab | donanemab | prolgolimab |
| ocrelizumab | osocimab | benufutamab | tralokinumab | IMGN779 | leronlimab | drozitumab | quavonlimab |
| ofatumumab | otlertuzumab | bexmarilimab | tremelimumab | IMMU-114 | naptumomab estafenatox | duligotuzumab | ragifilimab |
| olaratumab | oxelumab | BMS-986148 | ublituximab | izuralimab | roledumab | eldelumab | ravagalimab |
| omalizumab | ozanezumab | BMS-986178 | vadastuximab talirine | KHK2866 | visilizumab | emactuzumab | remtolumab |
| palivizumab | pamrevlumab | cetrelimab | zalutumumab | laprituximab emtansine | adebrelimab | EMD 273063 | revdofilimab |
| panitumumab | parsatuzumab | conatumumab | zanolimumab | lexatumumab | aducanumab | emibetuzumab | RG6125 |
| pembrolizumab | pateclizumab | crovalimab | zolbetuximab | lodapolimab | AMG 386 | enibarcimab | sapelizumab |
| pertuzumab | pepinemab | efungumab | 7A7 | lodelcizumab | andecaliximab | enokizumab | SAR252067 |
| polatuzumab vedotin-piiq | pidilizumab | enapotamab vedotin | AB-25E9 | losatuxizumab vedotin | anifrolumab | ensituximab | setoxaximab |
| ramucirumab | pimurutamab | epcoritamab | abelacimab | lumretuzumab | bapineuzumab | etaracizumab | spesolimab |
| ranibizumab | pinatuzumab vedotin | glenzocimab | abrezekimab | lupartumab amadotin | bavituximab | etokimab | sugemalimab |
| risankizumab | placulumab | indatuximab ravtansine | ABT-325 | LY2787106 | begelomab | ezabenlimab | tadocizumab |
| rituximab | plozalizumab | intetumumab | adalimumab beta | LY2928057 | bemarituzumab | fezakinumab | tafolecimab |
| romosozumab-aqqg | ponezumab | labetuzumab | APX007 | LY3022855 | bermekimab | ficlatuzumab | tebotelimab |
| sarilumab | pozelimab | letolizumab | AR20.5 | LY3022856 | bimekizumab | fletikumab | tenatumomab |
| secukinumab | prezalumab | lucatumumab | AS2886401-00 | LY3022859 | birtamimab | flotetuzumab | tilogotamab |
| siltuximab | pritoxaximab | magrolimab | AT001 | LY3076226 | bococizumab | fontolizumab | TRX1 |
| sintilimab | quetmolimab | mezagitamab | ATN-658 | MEDI 5117 | brazikumab | foralumab | upifitamab |
| tafasitamab-cxix | quilizumab | milatuzumab | axatilimab | MEDI3617 | briakinumab | foravirumab | urabrelimab |
| teprotumumab-trbw | racotumomab | monalizumab | BAY 1158061 | MEDI-547 | camrelizumab | fresolimumab | varisacumab |
| tildrakizumab-asmn | rafivirumab | mosunetuzumab | BMS-986012 | MEDI-570 | carotuximab | frovocimab | VB1-050 |
| tocilizumab | refanezumab | nidanilimab | BT-063 | MEDI-578 | clazakizumab | garadacimab | vixarelimab |
| toripalimab | relatlimab | ocaratuzumab | C705 | MINT1526A | clivatuzumab tetraxetan | garetosmab | zampilimab |
| trastuzumab | RG7652 | ozoralizumab | C836 |
|
| gimsilumab |
|
| trastuzumab emtansine | rinucumab | pacmilimab | cantuzumab ravtansine |
|
|
|
|
欢迎咨询我们业务人员了解更多详细信息!